Natera, Inc. (45E.F)
| Previous Close | 86.00 |
| Open | 84.00 |
| Bid | 0.00 x 29600 |
| Ask | 0.00 x 28500 |
| Day's Range | 84.00 - 86.50 |
| 52 Week Range | 49.00 - 103.00 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | 8.085B |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.60 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 150.11 |
Business WireNatera Announces Significant Milestone with 200+ Peer-Reviewed Publications
AUSTIN, Texas, April 22, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
Simply Wall St.Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Natera fair value estimate is US$119 Natera's US$96.71 share...
Business WireNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
AUSTIN, Texas, April 11, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here.
